TY - JOUR
T1 - Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure
AU - Guazzi, Marco
AU - Arena, Ross
AU - Pinkstaff, Sherry
AU - Guazzi, Maurizio D.
PY - 2009/8/21
Y1 - 2009/8/21
N2 - Previous research has demonstrated an increase in large vessel stiffness in patients with heart failure (HF). Furthermore, heart rate recovery (HRR) may be negatively impacted by increased arterial stiffness secondary to altered baroreceptor discharge. The purpose of the present study was to determine if chronic phosphodiesterase 5 (PDE5) inhibition with Sildenafil, previously shown to improve arterial stiffness, favorably impacts HRR in patients with HF. Forty male subjects (age: 65.3 ± 7.3 years, baseline ejection fraction: 37.1 ± 7.4%, 15 non-ischemic HF/25 ischemic HF) participated in this study. Subjects received Sildenafil (25 mg, 3 times/day) for six months. Symptom-limited exercise testing was performed at baseline and six months with a lower extremity ergometer. Heart rate recovery was defined as HR at maximal exercise minus HR at 1 min recovery. No adverse effects were reported throughout the study period. Paired t-testing revealed that HRR was significantly improved following six months of Sildenafil therapy (baseline: 17.5 ± 3.5 bpm vs. Post: 20.6 ± 3.2 bpm). The results of the present study indicate that chronic Sildenafil therapy significantly increases HRR, an important prognostic marker, in patients with HF. A plausible mechanism for the improvement of HRR is the previously demonstrated impact Sildenafil has on arterial stiffness and therefore baroreceptor function.
AB - Previous research has demonstrated an increase in large vessel stiffness in patients with heart failure (HF). Furthermore, heart rate recovery (HRR) may be negatively impacted by increased arterial stiffness secondary to altered baroreceptor discharge. The purpose of the present study was to determine if chronic phosphodiesterase 5 (PDE5) inhibition with Sildenafil, previously shown to improve arterial stiffness, favorably impacts HRR in patients with HF. Forty male subjects (age: 65.3 ± 7.3 years, baseline ejection fraction: 37.1 ± 7.4%, 15 non-ischemic HF/25 ischemic HF) participated in this study. Subjects received Sildenafil (25 mg, 3 times/day) for six months. Symptom-limited exercise testing was performed at baseline and six months with a lower extremity ergometer. Heart rate recovery was defined as HR at maximal exercise minus HR at 1 min recovery. No adverse effects were reported throughout the study period. Paired t-testing revealed that HRR was significantly improved following six months of Sildenafil therapy (baseline: 17.5 ± 3.5 bpm vs. Post: 20.6 ± 3.2 bpm). The results of the present study indicate that chronic Sildenafil therapy significantly increases HRR, an important prognostic marker, in patients with HF. A plausible mechanism for the improvement of HRR is the previously demonstrated impact Sildenafil has on arterial stiffness and therefore baroreceptor function.
KW - Arterial stiffness
KW - Autonomic tone
KW - Baroreceptor
UR - http://www.scopus.com/inward/record.url?scp=68049100153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68049100153&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2008.04.061
DO - 10.1016/j.ijcard.2008.04.061
M3 - Article
C2 - 18667251
AN - SCOPUS:68049100153
VL - 136
SP - 341
EP - 343
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 3
ER -